Literature DB >> 14879042

A case of myxoedema developing during p-aminosalicylic acid therapy.

G M KOMROWER.   

Abstract

Entities:  

Keywords:  MYXEDEMA/etiology and pathogenesis; PARA-AMINOSALICYLIC ACID/toxicity

Mesh:

Substances:

Year:  1951        PMID: 14879042      PMCID: PMC2070762          DOI: 10.1136/bmj.2.4741.1193

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  3 in total

1.  Para-aminosalicylic acid treatment of tuberculosis; a review.

Authors:  E BOGEN; R N LOOMIS; D W WILL
Journal:  Am Rev Tuberc       Date:  1950-02

2.  Paraaminosalicylic acid in tuberculosis; clinical and pharmacological aspects.

Authors:  D G MADIGAN; L L GRIFFITHS
Journal:  Lancet       Date:  1950-02-11       Impact factor: 79.321

3.  Para-aminosalicylic acid (Pas) in pulmonary and extrapulmonary tuberculosis.

Authors:  B CARSTENSEN
Journal:  Am Rev Tuberc       Date:  1950-05
  3 in total
  8 in total

1.  TERMINAL HYPERKALEMIA.

Authors:  R K CHANDRA
Journal:  Indian J Pediatr       Date:  1963-09       Impact factor: 1.967

2.  The hypersensitivity reactions to para-aminosalicylic acid (P.A.S.).

Authors:  S CARNE
Journal:  Arch Dis Child       Date:  1957-10       Impact factor: 3.791

3.  Hyperthyroidism developing during P.A.S. therapy.

Authors:  S TANDHANAND; R BURI
Journal:  Br Med J       Date:  1956-08-04

4.  Thyroid disorders in childhood.

Authors:  D HUBBLE
Journal:  Br Med J       Date:  1956-04-21

5.  Radio-iodine measurements of thyroid function during and after P.A.S. treatment of tuberculosis.

Authors:  J A BALINT; R FRASER; M G HANNO
Journal:  Br Med J       Date:  1954-05-29

6.  Effect of P.A.S. on the thyroid gland.

Authors:  R R HAMILTON
Journal:  Br Med J       Date:  1953-01-03

7.  Goitre and hypothyroidism developing during treatment with P.A.S.

Authors:  H T DAVIES; H J B GALBRAITH
Journal:  Br Med J       Date:  1953-06-06

Review 8.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.